COMP <GO>
XYL vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Xylem Inc. Common Stock New (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: XYL 7
— TMO 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TMO
LAST: $92.40 (+1.81%) • MKT CAP: $20.81B
balance-sheet
3.28
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XYL VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XYL | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 38.50% | 41.00% | -2.50 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.50% | 9.30% | -0.80 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.2x | 30.4x | -17.20 | XYL | /valuation <GO> |
| Free Cash Flow Yield | 4.01% | 2.40% | +1.61 | XYL | /fcf-yield <GO> |
| Operating Margin | 13.50% | 17.40% | -3.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 10.60% | 15.10% | -4.50 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | 3.90% | +1.60 | XYL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.88% | 0.24% | +1.64 | XYL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.28 | 4.50 | -1.22 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | XYL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.70% | -0.10 | XYL | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.5 | 59.1 | -25.70 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.94 | -0.03 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.2x | 36.3x | -16.10 | XYL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $20.81B | $262.22B | -$241.40B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XYL REV | TMO REV | XYL GROSS % | TMO GROSS % | XYL FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.04B | $44.56B | 38.5% | 44.0% | $834.4M | $6.29B |
| FY 2024 | $8.56B | $42.88B | 37.5% | 44.0% | $877.7M | $7.27B |
| FY 2023 | $7.36B | $42.86B | 44.0% | 44.0% | $505.6M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XYL // BETA 0.91
TMO // BETA 0.94